title: Itch Management: Systemic Agents.
abstract: Itch is a global clinical problem and finding effective treatment remains a therapeutic challenge because of the complex pathophysiology of itch. The key component of treating itch should be directed at the underlying etiologies when possible. However, without eradication of the underlying diseases, treatment is often palliative at best. Treatment with systemic therapies can vary according to the etiology of the chronic itch. The aim of this article is to review the major systemic anti-itch agents and give a summary on the possible systemic treatments for different types of itch.
authors: Padcha
authors: P
authors: Pongcharoen
authors: Alan B
authors: AB
authors: Fleischer
mesh_terms: D000588:Amines / Q000627:therapeutic use; D000700:Analgesics / Q000627:therapeutic use*; D000701:Analgesics, Opioid / Q000627:therapeutic use*; D000837:Anion Exchange Resins / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D000077608:Aprepitant; D002756:Cholagogues and Choleretics / Q000627:therapeutic use; D002779:Cholestasis / Q000150:complications / Q000188:drug therapy; D002792:Cholestyramine Resin / Q000627:therapeutic use; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use; D000077206:Gabapentin; D006633:Histamine Antagonists / Q000627:therapeutic use*; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D064729:Neurokinin-1 Receptor Antagonists / Q000627:therapeutic use; D010257:Paraneoplastic Syndromes / Q000150:complications / Q000188:drug therapy; D010523:Peripheral Nervous System Diseases / Q000150:complications / Q000188:drug therapy; D000069583:Pregabalin / Q000627:therapeutic use; D011537:Pruritus / Q000188:drug therapy* / Q000209:etiology; D017473:Receptors, Opioid, kappa / Q000819:agonists; D017450:Receptors, Opioid, mu / Q000037:antagonists & inhibitors; D012293:Rifampin / Q000627:therapeutic use; D013792:Thalidomide / Q000627:therapeutic use; D014511:Uremia / Q000150:complications / Q000188:drug therapy; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use
chemical_list: D000588:Amines; D000700:Analgesics; D000701:Analgesics, Opioid; D000837:Anion Exchange Resins; D000928:Antidepressive Agents; D002756:Cholagogues and Choleretics; D003509:Cyclohexanecarboxylic Acids; D006633:Histamine Antagonists; D009025:Morpholines; D009292:Narcotic Antagonists; D064729:Neurokinin-1 Receptor Antagonists; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu; D002792:Cholestyramine Resin; D000077608:Aprepitant; D013792:Thalidomide; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D014580:Ursodeoxycholic Acid; D012293:Rifampin